Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s37, 2020. DOI: 10.25251/skin.4.supp.37. Disponível em: https://skin.dermsquared.com/skin/article/view/986. Acesso em: 13 apr. 2025.